Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer

J. N. Ingle, J. E. Krook, J. A. Mailliard, L. C. Hartmann, H. S. Wieand

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity. The introduction of mesna as a uroprotective agent provided a stimulus for reexamination of ifosfamide for therapy of women with metastatic breast cancer. Twenty women with measurable (18 patients) or evaluable (2 patients) disease were entered into a phase II clinical trial of ifosfamide plus mesna as first-line chemotherapy. Ifosfamide was administered i.v. at a dose of 1,800 mg/m2 in 1 L D5W over 2 h on five consecutive days. Mesna was administered i.v. at a dose of 400 mg/m2 over 15 min immediately before and 1 h after ifosfamide, and then every 4 h for three more doses. The last three doses could be given either i.v. or orally. The planned cycle length was 28 days. Three patients (15%), all with measurable disease, achieved a partial response (95% confidence interval: 3 to 38%). Median time to progression was 137 days and median survival was 407 days. Toxicities included cumulative myelosuppression and substantial nausea and emesis. Four patients were removed from treatment because of toxicity alone and a fifth refused further therapy. We conclude that ifosfamide, plus mesna, as given in this protocol has definite but limited antitumor activity and poor tolerability.

Original languageEnglish (US)
Pages (from-to)498-501
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume18
Issue number6
StatePublished - 1995

Fingerprint

Mesna
Ifosfamide
Breast Neoplasms
Drug Therapy
Phase II Clinical Trials
Cyclophosphamide
Nausea
Vomiting
Therapeutics
Confidence Intervals
Survival

Keywords

  • Chemotherapy
  • Ifosfamide
  • Mesna
  • Metastatic breast cancer
  • Phase II clinical trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. / Ingle, J. N.; Krook, J. E.; Mailliard, J. A.; Hartmann, L. C.; Wieand, H. S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 18, No. 6, 1995, p. 498-501.

Research output: Contribution to journalArticle

Ingle, J. N. ; Krook, J. E. ; Mailliard, J. A. ; Hartmann, L. C. ; Wieand, H. S. / Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1995 ; Vol. 18, No. 6. pp. 498-501.
@article{0ca6f3d416564d5289260694eadb8c01,
title = "Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer",
abstract = "Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity. The introduction of mesna as a uroprotective agent provided a stimulus for reexamination of ifosfamide for therapy of women with metastatic breast cancer. Twenty women with measurable (18 patients) or evaluable (2 patients) disease were entered into a phase II clinical trial of ifosfamide plus mesna as first-line chemotherapy. Ifosfamide was administered i.v. at a dose of 1,800 mg/m2 in 1 L D5W over 2 h on five consecutive days. Mesna was administered i.v. at a dose of 400 mg/m2 over 15 min immediately before and 1 h after ifosfamide, and then every 4 h for three more doses. The last three doses could be given either i.v. or orally. The planned cycle length was 28 days. Three patients (15{\%}), all with measurable disease, achieved a partial response (95{\%} confidence interval: 3 to 38{\%}). Median time to progression was 137 days and median survival was 407 days. Toxicities included cumulative myelosuppression and substantial nausea and emesis. Four patients were removed from treatment because of toxicity alone and a fifth refused further therapy. We conclude that ifosfamide, plus mesna, as given in this protocol has definite but limited antitumor activity and poor tolerability.",
keywords = "Chemotherapy, Ifosfamide, Mesna, Metastatic breast cancer, Phase II clinical trial",
author = "Ingle, {J. N.} and Krook, {J. E.} and Mailliard, {J. A.} and Hartmann, {L. C.} and Wieand, {H. S.}",
year = "1995",
language = "English (US)",
volume = "18",
pages = "498--501",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer

AU - Ingle, J. N.

AU - Krook, J. E.

AU - Mailliard, J. A.

AU - Hartmann, L. C.

AU - Wieand, H. S.

PY - 1995

Y1 - 1995

N2 - Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity. The introduction of mesna as a uroprotective agent provided a stimulus for reexamination of ifosfamide for therapy of women with metastatic breast cancer. Twenty women with measurable (18 patients) or evaluable (2 patients) disease were entered into a phase II clinical trial of ifosfamide plus mesna as first-line chemotherapy. Ifosfamide was administered i.v. at a dose of 1,800 mg/m2 in 1 L D5W over 2 h on five consecutive days. Mesna was administered i.v. at a dose of 400 mg/m2 over 15 min immediately before and 1 h after ifosfamide, and then every 4 h for three more doses. The last three doses could be given either i.v. or orally. The planned cycle length was 28 days. Three patients (15%), all with measurable disease, achieved a partial response (95% confidence interval: 3 to 38%). Median time to progression was 137 days and median survival was 407 days. Toxicities included cumulative myelosuppression and substantial nausea and emesis. Four patients were removed from treatment because of toxicity alone and a fifth refused further therapy. We conclude that ifosfamide, plus mesna, as given in this protocol has definite but limited antitumor activity and poor tolerability.

AB - Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity. The introduction of mesna as a uroprotective agent provided a stimulus for reexamination of ifosfamide for therapy of women with metastatic breast cancer. Twenty women with measurable (18 patients) or evaluable (2 patients) disease were entered into a phase II clinical trial of ifosfamide plus mesna as first-line chemotherapy. Ifosfamide was administered i.v. at a dose of 1,800 mg/m2 in 1 L D5W over 2 h on five consecutive days. Mesna was administered i.v. at a dose of 400 mg/m2 over 15 min immediately before and 1 h after ifosfamide, and then every 4 h for three more doses. The last three doses could be given either i.v. or orally. The planned cycle length was 28 days. Three patients (15%), all with measurable disease, achieved a partial response (95% confidence interval: 3 to 38%). Median time to progression was 137 days and median survival was 407 days. Toxicities included cumulative myelosuppression and substantial nausea and emesis. Four patients were removed from treatment because of toxicity alone and a fifth refused further therapy. We conclude that ifosfamide, plus mesna, as given in this protocol has definite but limited antitumor activity and poor tolerability.

KW - Chemotherapy

KW - Ifosfamide

KW - Mesna

KW - Metastatic breast cancer

KW - Phase II clinical trial

UR - http://www.scopus.com/inward/record.url?scp=0029557406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029557406&partnerID=8YFLogxK

M3 - Article

C2 - 8526193

AN - SCOPUS:0029557406

VL - 18

SP - 498

EP - 501

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 6

ER -